Consolidated Statements of Comprehensive Loss (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenues:
Clinical treatment programs	$ 161	$ 135	$ 111
Total Revenues	161	135	111
Costs and Expenses:
Production/cost of goods sold	1,043	1,341	584
Research and development	6,722	7,613	6,995
General and administrative	6,691	7,568	5,796
Total Costs and Expenses	14,456	16,522	13,375
Operating loss	(14,295)	(16,387)	(13,264)
Interest and other income	624	2,383	67
Interest expense	(41)	(11)	0
Financing costs from standby financing agreement	0	0	(241)
Funds received from sale of income tax operating losses	2,272	0	0
Redeemable warrants valuation adjustment	2,425	879	6,258
Net loss	(9,015)	(13,136)	(7,180)
Other Comprehensive Income:
Unrealized losses on securities	(311)	(1,013)	0
Less: Premium amortization and realized losses	896	39	0
Net comprehensive loss	$ (8,430)	$ (14,110)	$ (7,180)
Basic and diluted loss per share	$ (0.07)	$ (0.10)	$ (0.07)
Weighted average shares outstanding basic and diluted	135,432,395	134,018,243	109,514,401